

Figure 1. Anti-Cln101 MAbs Epitope Map




Figure 2. Detection of Cln101 in Normal and Cancer Serum Samples (primary panel)




Figure 3. Detection of Cln101 in Normal and Cancer Serum Samples (primary panel), Expanded Scale




Figure 4. Detection of Cln101 in Normal and Cancer Serum Samples (multiple panels)




Figure 5. Detection of Cln101 in Normal and Cancer Serum Samples (multiple panels), Expanded Scale




Figure 6. Detection of Cln101 in Normal and Cancer Serum Samples (master panel)




Figure 7. Detection of Cln101 in Normal and Cancer Serum Samples (master panel), Expanded Scale




Figure 8. Detection of Cln101 in Normal, Prostate Cancer and Prostate Benign Serum Samples




Figure 9. Detection of PSA in Normal, Prostate Cancer and Prostate Benign Serum Samples





Figure 10. Detection of Cln101 in Normal, Ovarian Cancer and Ovarian Benign Serum Samples



X Labels	ProMdx normal	Ovarian Cancer	Endometriosis	dDx normal
Number of values	31	57	24	13
Minimum	0.0070	0.0270	0.0070	0.0030
25% Percentile	0.0210	0.1470	0.0155	0.0070
Median	0.0370	0.2680	0.0270	0.0110
75% Percentile	0.0610	0.3860	0.0370	0.0260
Maximum	0.6760	1.689	0.1710	0.0380

Figure 11. ROC Curves for CLN101 and PSA in Prostate Cancer vs. Normal Serum Samples




Figure 12. ROC Curves for CLN101 and PSA in Prostate Cancer and Benign Disease vs. Normal Serum Samples

